All In Biotech

Drug Trial Radar · NCT06615479

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 440 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

440

Planned (sponsor's estimate)

Start

Mar 12, 2025

Primary completion

Dec 30, 2027

Study completion Jun 22, 2032

Sponsor

Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Celgene Corporation
First posted
Sep 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

Conditions

  • Relapsed or Refractory Multiple Myeloma (RRMM)

Interventions

  • BMS-986393Drug

    Specified dose on specified days

  • CyclophosphamideDrug

    Specified dose on specified days

  • FludarabineDrug

    Specified dose on specified days

  • DaratumumabDrug

    Specified dose on specified days

  • PomalidomideDrug

    Specified dose on specified days

  • DexamethasoneDrug

    Specified dose on specified days

  • CarfilzomibDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to 5 years after the last participant is randomized
  2. Minimal residual disease (MRD)-negativity in complete response (CR)Time frame: Up to 1 year after the last participant is randomized

Locations

141 sites in 31 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • UCLA Hematology/Oncology - Santa Monica

    Los Angeles, California · Recruiting

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center

    Orange, California · Recruiting

  • Georgetown University Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Baptist MD Anderson Cancer Center

    Jacksonville, Florida · Recruiting

  • University of Miami Hospital and Clinics, Sylvester Cancer Center

    Miami, Florida · Recruiting

  • Local Institution - 0228

    Orlando, Florida · Withdrawn

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia · Recruiting

  • Louisiana State University Health Sciences Shreveport

    Shreveport, Louisiana · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Local Institution - 0219

    Minneapolis, Minnesota · Withdrawn

  • Weill Cornell Medical College

    New York, New York · Recruiting

  • Local Institution - 0221

    Stony Brook, New York · Withdrawn

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Local Institution - 0097

    Philadelphia, Pennsylvania · Active not recruiting

  • AHN West Penn Hospital

    Pittsburgh, Pennsylvania · Recruiting

  • Local Institution - 0227

    Charleston, South Carolina · Withdrawn

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Hospital Italiano de Buenos Aires

    ABB, Buenos Aires F.D., Argentina · Recruiting

  • Local Institution - 0214

    ABB, Buenos Aires F.D., Argentina · Withdrawn

  • Hospital Aleman

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Local Institution - 0142

    Camperdown, New South Wales, Australia · Active not recruiting

  • Local Institution - 0190

    Liverpool, New South Wales, Australia · Active not recruiting

  • Local Institution - 0140

    Brisbane, Queensland, Australia · Active not recruiting

  • Local Institution - 0139

    Adelaide, South Australia, Australia · Active not recruiting

  • Local Institution - 0143

    Clayton, Victoria, Australia · Active not recruiting

  • Local Institution - 0138

    Melbourne, Victoria, Australia · Active not recruiting

  • Local Institution - 0191

    Melbourne, Victoria, Australia · Active not recruiting

  • Local Institution - 0141

    Murdoch, Western Australia, Australia · Active not recruiting

  • Hanusch-Krankenhaus

    Vienna, Austria · Recruiting

  • Ordensklinikum Linz GmbH Elisabethinen

    Linz, Upper Austria, Austria · Recruiting

  • Antwerp University Hospital

    Edegem, Antwerpen, Belgium · Recruiting

  • Cliniques universitaires Saint-Luc

    Brussels, Bruxelles-Capitale, Région de, Belgium · Recruiting

  • Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godinne

    Yvoir, Namur, Belgium · Recruiting

  • UZ Gent

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • Instituto D'Or de Pesquisa e Ensino (IDOR)

    São Paulo, Brazil · Recruiting

Showing 40 of 141 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.